GlassScriptPhysician profile
David A Theobald
NPI 1588003859
$1,723.83
in general payments reported to CMS, 2019-2025
23 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.75 · 2023: $34.56 · 2024: $278 · 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $345.16 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $170.86 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.58 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $138.79 | 2024-2025 | |
| Novo Nordisk INC | $107.33 | 2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $87.16 | 2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $85.73 | 2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $79.75 | 2021 | |
| Sumitomo Pharma America, INC. | $76.46 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $67.32 | 2025 | Rexulti |
| Abbvie INC. | $55.12 | 2025 | |
| Seqirus USA INC | $51.35 | 2024 | |
| Genentech USA, INC. | $44.27 | 2024 | Xolair |
| Pfizer INC. | $38.59 | 2025 | |
| Cardiovascular Systems INC. | $34.56 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $30.16 | 2025 | Tymlos |
| Dexcom, INC. | $24.83 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $24.71 | 2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $24.57 | 2025 | The Cologuard Plus Collection Kit |
| Vertex Pharmaceuticals Incorporated | $21.91 | 2025 | |
| Intuitive Surgical, INC. | $18.96 | 2024 | |
| Paratek Pharmaceuticals, INC. | $16.88 | 2025 | Nuzyra, Xhance |
| Philips North America LLC | $15.78 | 2024 | (Cm9) Amb Mon & Diag Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Theobald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.